vs
Employers Holdings, Inc.（EIG）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Employers Holdings, Inc.的1.2倍（$207.3M vs $170.5M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -21.3%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -11.4%）
Employers Holdings, Inc.是总部位于美国的保险控股企业，主营劳工赔偿保险产品，主要面向美国境内中小微企业客户，同时提供定制化风险管理解决方案，服务覆盖多类中低风险行业，助力客户管控工作场所安全风险、满足员工保障相关合规要求。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EIG vs RARE — 直观对比
营收规模更大
RARE
是对方的1.2倍
$170.5M
营收增速更快
RARE
高出47.2%
-21.3%
两年增速更快
RARE
近两年复合增速
-11.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $170.5M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | -21.3% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EIGRARE
| Q1 26 | $170.5M | — | ||
| Q4 25 | $188.5M | $207.3M | ||
| Q3 25 | $239.3M | $159.9M | ||
| Q2 25 | $246.3M | $166.5M | ||
| Q1 25 | $202.6M | $139.3M | ||
| Q4 24 | $216.6M | $164.6M | ||
| Q3 24 | $224.0M | $139.5M | ||
| Q2 24 | $217.0M | $147.0M |
净利润EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $-8.3M | $-180.4M | ||
| Q2 25 | $29.7M | $-115.0M | ||
| Q1 25 | $12.8M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $30.3M | $-133.5M | ||
| Q2 24 | $31.7M | $-131.6M |
营业利润率EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | — | -54.7% | ||
| Q3 25 | -4.7% | -106.9% | ||
| Q2 25 | 15.0% | -64.8% | ||
| Q1 25 | 7.8% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 16.4% | -94.6% | ||
| Q2 24 | 18.4% | -79.1% |
净利率EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | — | -62.0% | ||
| Q3 25 | -3.5% | -112.8% | ||
| Q2 25 | 12.1% | -69.0% | ||
| Q1 25 | 6.3% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 13.5% | -95.7% | ||
| Q2 24 | 14.6% | -89.5% |
每股收益（稀释后）EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | $-0.93 | $-1.28 | ||
| Q3 25 | $-0.36 | $-1.81 | ||
| Q2 25 | $1.23 | $-1.17 | ||
| Q1 25 | $0.52 | $-1.57 | ||
| Q4 24 | $1.14 | $-1.34 | ||
| Q3 24 | $1.21 | $-1.40 | ||
| Q2 24 | $1.25 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $169.9M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $955.7M | $-80.0M |
| 总资产 | $3.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EIGRARE
| Q1 26 | $169.9M | — | ||
| Q4 25 | $169.9M | $421.0M | ||
| Q3 25 | $172.4M | $202.5M | ||
| Q2 25 | $78.1M | $176.3M | ||
| Q1 25 | $100.4M | $127.1M | ||
| Q4 24 | $68.4M | $174.0M | ||
| Q3 24 | $173.9M | $150.6M | ||
| Q2 24 | $126.4M | $480.7M |
总债务EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | $19.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EIGRARE
| Q1 26 | $955.7M | — | ||
| Q4 25 | $955.7M | $-80.0M | ||
| Q3 25 | $1.0B | $9.2M | ||
| Q2 25 | $1.1B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.1B | $255.0M | ||
| Q3 24 | $1.1B | $346.8M | ||
| Q2 24 | $1.0B | $432.4M |
总资产EIGRARE
| Q1 26 | $3.4B | — | ||
| Q4 25 | $3.4B | $1.5B | ||
| Q3 25 | $3.5B | $1.2B | ||
| Q2 25 | $3.5B | $1.3B | ||
| Q1 25 | $3.6B | $1.3B | ||
| Q4 24 | $3.5B | $1.5B | ||
| Q3 24 | $3.6B | $1.5B | ||
| Q2 24 | $3.5B | $1.6B |
负债/权益比EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | 0.02× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | $44.7M | $-99.8M | ||
| Q3 25 | $29.4M | $-91.4M | ||
| Q2 25 | $0 | $-108.3M | ||
| Q1 25 | $14.6M | $-166.5M | ||
| Q4 24 | $76.4M | $-79.3M | ||
| Q3 24 | $51.0M | $-67.0M | ||
| Q2 24 | $11.7M | $-77.0M |
自由现金流EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | $44.6M | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | $76.3M | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
自由现金流率EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | 23.7% | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | 35.2% | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
资本支出强度EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
现金转化率EIGRARE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 1.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.68× | — | ||
| Q2 24 | 0.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EIG
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
